Tag: LCIS

Articles

• Breast cancer types
• Lobular breast cancer and LCIS characteristics

News

06/02/15

Local recurrence rates for LCIS can be significant

03/16/14

Over 80% of women diagnosed with DCIS or LCIS do not progress

04/28/12

Ki67 proliferation index predicts progression of LCIS

06/24/11

Multifocal breast cancer has worse prognosis than single tumors

Studies

• Trajectory of Subsequent Breast Cancer Diagnoses in a Diverse Patient Cohort with Breast Atypia Cite
  Limberg JN, Thomas SM, Dalton JC, Ntowe KW, Nash AL, Chiba A, et al. Trajectory of Subsequent Breast Cancer Diagnoses in a Diverse Patient Cohort with Breast Atypia. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2024; 10.1245/s10434-024-15788-7
• Atypical lobular hyperplasia: what we need to know Cite
  Ferre R, Kuzmiak CM. Atypical lobular hyperplasia: what we need to know. Journal of Medical Imaging and Interventional Radiology. Springer Science and Business Media LLC; 2024; 11 10.1007/s44326-024-00011-4
• Use of beta-blockers in patients with ductal carcinoma in situ and risk of invasive breast cancer recurrence: a Swedish retrospective cohort study Cite
  Strell C, Smith DR, Valachis A, Woldeyesus H, Wadsten C, Micke P, et al. Use of beta-blockers in patients with ductal carcinoma in situ and risk of invasive breast cancer recurrence: a Swedish retrospective cohort study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07358-y
• Immediate and delayed risk of breast cancer associated with classic lobular carcinoma in situ and its variants Cite
  Chung HL, Middleton LP, Sun J, Whitman GJ. Immediate and delayed risk of breast cancer associated with classic lobular carcinoma in situ and its variants. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07261-6
• Upgrade rates of variant lobular carcinoma in-situ (LCIS) compared to classic LCIS diagnosed in core needle biopsies: A ten-year single institution retrospective study Cite
  Harinath L, Villatoro TM, Clark BZ, Fine JL, Yu J, Carter GJ, et al. Upgrade rates of variant lobular carcinoma in-situ (LCIS) compared to classic LCIS diagnosed in core needle biopsies: A ten-year single institution retrospective study. Modern Pathology. Elsevier BV; 2024;:100462 10.1016/j.modpat.2024.100462
• Atypical Ductal Hyperplasia and Lobular In Situ Neoplasm: High-Risk Lesions Challenging Breast Cancer Prevention Cite
  Nicosia L, Mariano L, Pellegrino G, Ferrari F, Pesapane F, Bozzini AC, et al. Atypical Ductal Hyperplasia and Lobular In Situ Neoplasm: High-Risk Lesions Challenging Breast Cancer Prevention. Cancers. MDPI AG; 2024; 16:837 10.3390/cancers16040837
• In situ breast cancer surgeries in Sweden: lumpectomy or mastectomy?—a cost-effectiveness analysis over a 30-Year period using Markov model Cite
  Pham PD, Muchadeyi MT, Lindholm L. In situ breast cancer surgeries in Sweden: lumpectomy or mastectomy?—a cost-effectiveness analysis over a 30-Year period using Markov model. Cost Effectiveness and Resource Allocation. Springer Science and Business Media LLC; 2023; 21 10.1186/s12962-023-00495-z
• Does Non-Classic Lobular Carcinoma In Situ at the Lumpectomy Margin Increase Local Recurrence? Cite
  Beck AC, Bayard S, Plitas G, Sevilimedu V, Kuba MG, Garcia P, et al. Does Non-Classic Lobular Carcinoma In Situ at the Lumpectomy Margin Increase Local Recurrence?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 30:6061-6069 10.1245/s10434-023-13899-1
• Management of screening-detected lobular neoplasia in the era of digital breast tomosynthesis: A preliminary study Cite
  Gao Y, Bahl M. Management of screening-detected lobular neoplasia in the era of digital breast tomosynthesis: A preliminary study. Clinical Imaging. Elsevier BV; 2023;:109979 10.1016/j.clinimag.2023.109979
• Absence of Lobular Carcinoma In Situ is a Poor Prognostic Marker in Invasive Lobular Carcinoma Cite
  Mouabbi JA, Raghavendra AS, Bassett RL, Christgen M, Middleton L, Teshome M, et al. Absence of Lobular Carcinoma In Situ is a Poor Prognostic Marker in Invasive Lobular Carcinoma. European Journal of Cancer. Elsevier BV; 2023;:113250 10.1016/j.ejca.2023.113250
• Management of Lobular Neoplasia Diagnosed by Core Biopsy Cite
  Jani C, Lotz M, Keates S, Gupta Y, Walker A, Al Omari O, et al. Management of Lobular Neoplasia Diagnosed by Core Biopsy. The Breast Journal. Hindawi Limited; 2023; 2023:1-9 10.1155/2023/8185446
• Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS Cite
  Nakhlis F, Katlin FD, Grossmith SC, DiPasquale A, Harrison BT, Schnitt SJ, et al. Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2022; 10.1245/s10434-022-12066-2
• Low-dose tamoxifen for breast cancer prevention in patients with ductal carcinoma in situ (DCIS) and atypical lesions: A real-world experience. Cite
  Patel R, Jin C, Tiersten A. Low-dose tamoxifen for breast cancer prevention in patients with ductal carcinoma in situ (DCIS) and atypical lesions: A real-world experience.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022; 40:e12537-e12537 10.1200/jco.2022.40.16_suppl.e12537
• Accuracy of the Breast Cancer Surveillance Consortium Model Among Women with LCIS Cite
  Eroglu I, Sevilimedu V, Park A, King TA, Pilewskie ML. Accuracy of the Breast Cancer Surveillance Consortium Model Among Women with LCIS. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 194:257-264 10.1007/s10549-021-06499-8
• Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease Cite
  DeCensi A, Puntoni M, Johansson H, Guerrieri-Gonzaga A, Caviglia S, Avino F, et al. Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease. Clinical Cancer Research. American Association for Cancer Research (AACR); 2021; 27:3576-3583 10.1158/1078-0432.ccr-20-4213
• Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen Cite
  Bychkovsky B, Laws A, Katlin F, Hans M, Knust Graichen M, Pace LE, et al. Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06577-5
• Prognostic Significance of Lobular Carcinoma In-Situ (LCIS) Diagnosed Alongside Invasive Breast Cancer Cite
  Braasch MC, Amin AL, Balanoff CR, Wagner JL, Larson KE. Prognostic Significance of Lobular Carcinoma In-Situ (LCIS) Diagnosed Alongside Invasive Breast Cancer. Breast Cancer: Basic and Clinical Research. SAGE Publications; 2022; 16:117822342110702 10.1177/11782234211070217
• Morphologic subtypes of lobular carcinoma in situ diagnosed on core needle biopsy: clinicopathologic features and findings at follow-up excision Cite
  Kuba MG, Murray MP, Coffey K, Calle C, Morrow M, Brogi E. Morphologic subtypes of lobular carcinoma in situ diagnosed on core needle biopsy: clinicopathologic features and findings at follow-up excision. Modern Pathology. Springer Science and Business Media LLC; 2021; 34:1495-1506 10.1038/s41379-021-00796-9
• Lobular carcinoma in situ – A pragmatic approach to the controversies Cite
  Brock J. Lobular carcinoma in situ – A pragmatic approach to the controversies. Human Pathology Reports. Elsevier BV; 2022; 27:300589 10.1016/j.hpr.2022.300589
• Trends in incidence, treatment, survival and subsequent breast cancer in lobular carcinoma in situ in the Netherlands: A population-based analysis Cite
  van Maaren MC, Ávila AO, van Manen JG, Menke-Pluijmers MB, Veltman J, Bart J, et al. Trends in incidence, treatment, survival and subsequent breast cancer in lobular carcinoma in situ in the Netherlands: A population-based analysis. The Breast. Elsevier BV; 2021; 10.1016/j.breast.2021.07.020
• Can breast cancer be stopped? Modifiable risk factors of breast cancer among women with a prior benign or premalignant lesion Cite
  Lilleborge M, Falk RS, Sørlie T, Ursin G, Hofvind S. Can breast cancer be stopped? Modifiable risk factors of breast cancer among women with a prior benign or premalignant lesion. International Journal of Cancer. Wiley; 2021; 10.1002/ijc.33680
• The lobular neoplasia enigma: management and prognosis in a long follow-up case series Cite
  Metovic J, Abate SO, Borella F, Vissio E, Bertero L, Mariscotti G, et al. The lobular neoplasia enigma: management and prognosis in a long follow-up case series. World Journal of Surgical Oncology. Springer Science and Business Media LLC; 2021; 19 10.1186/s12957-021-02182-w
• Relationship Between Proliferative Breast Lesions and Breast Cancer Risk Factors Cite
  Toktaş O, Elasan S, İliklerden ÜH, Erten R, Karayil AR, Özdemir A, et al. Relationship Between Proliferative Breast Lesions and Breast Cancer Risk Factors. European Journal of Breast Health. Galenos Yayinevi; 2021; 17:15-20 10.4274/ejbh.2020.5713
• Lobular intraepithelial neoplasia: Outcomes and optimal management Cite
  Boland PA, Dunne EC, Kovanaite A, Stokes M, Kell MR, Barry JM, et al. Lobular intraepithelial neoplasia: Outcomes and optimal management. The Breast Journal. Wiley; 2020; 26:2383-2390 10.1111/tbj.14117
• Longitudinal study of breast cancer risk markers Cite
  Zarwan C, Diamond O, Lam P, Ghebremichael MS, Lotz M, Shen AH, et al. Longitudinal study of breast cancer risk markers. The Breast Journal. Wiley; 2020; 10.1111/tbj.14097
• Apocrine Variant of Pleomorphic Lobular Carcinoma In Situ Cite
  Zhong E, Solomon JP, Cheng E, Baum J, Song W, Hoda SA. Apocrine Variant of Pleomorphic Lobular Carcinoma In Situ. American Journal of Surgical Pathology. Ovid Technologies (Wolters Kluwer Health); 2020; 44:1092-1103 10.1097/pas.0000000000001493
• Lobular carcinoma in situ: diagnostic criteria and molecular correlates Cite
  Sokolova A, Lakhani SR. Lobular carcinoma in situ: diagnostic criteria and molecular correlates. Modern Pathology. Springer Science and Business Media LLC; 2020; 10.1038/s41379-020-00689-3
• Disparities in Risk Reduction Therapy Recommendations for Young Women With Lobular Carcinoma In-Situ Cite
  Bandera BC, Voci A, Nelson DW, Stern S, Barrak D, Fischer TD, et al. Disparities in Risk Reduction Therapy Recommendations for Young Women With Lobular Carcinoma In-Situ. Clinical Breast Cancer. Elsevier BV; 2020; 20:e397-e402 10.1016/j.clbc.2020.01.006
• Upgrade at excisional biopsy after a core needle biopsy diagnosis of classic lobular carcinoma in situ Cite
  Pride RM, Jimenez RE, Hoskin TL, Degnim AC, Hieken TJ. Upgrade at excisional biopsy after a core needle biopsy diagnosis of classic lobular carcinoma in situ. Surgery. Elsevier BV; 2020; 10.1016/j.surg.2020.07.025
• Do Body Mass Index and Breast Density Impact Cancer Risk Among Women with Lobular Carcinoma In Situ? Cite
  Minami CA, Zabor EC, Gilbert E, Newman A, Park A, Jochelson MS, et al. Do Body Mass Index and Breast Density Impact Cancer Risk Among Women with Lobular Carcinoma In Situ?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 27:1844-1851 10.1245/s10434-019-08126-9
• The Tyrer–Cuzick Model Inaccurately Predicts Invasive Breast Cancer Risk in Women With LCIS Cite
  Valero MG, Zabor EC, Park A, Gilbert E, Newman A, King TA, et al. The Tyrer–Cuzick Model Inaccurately Predicts Invasive Breast Cancer Risk in Women With LCIS. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2019; 27:736-740 10.1245/s10434-019-07814-w
• Genetic analysis of pleomorphic and florid lobular carcinoma in situ variants: frequent ERBB2/ERBB3 alterations and clonal relationship to classic lobular carcinoma in situ and invasive lobular carcinoma Cite
  Shamir ER, Chen Y, Krings G. Genetic analysis of pleomorphic and florid lobular carcinoma in situ variants: frequent ERBB2/ERBB3 alterations and clonal relationship to classic lobular carcinoma in situ and invasive lobular carcinoma. Modern Pathology. Springer Science and Business Media LLC; 2020; 33:1078-1091 10.1038/s41379-019-0449-8
• Associations of race and ethnicity with risk of developing invasive breast cancer after lobular carcinoma in situ Cite
  Dania V, Liu Y, Ademuyiwa F, Weber JD, Colditz GA. Associations of race and ethnicity with risk of developing invasive breast cancer after lobular carcinoma in situ. Breast Cancer Research. Springer Science and Business Media LLC; 2019; 21 10.1186/s13058-019-1219-8
• Why Breast Cancer Risk Models Fail: The Case of Lobular Carcinoma In Situ Cite
  Euhus DM. Why Breast Cancer Risk Models Fail: The Case of Lobular Carcinoma In Situ. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2019; 27:627-629 10.1245/s10434-019-07875-x
• Medication Use to Reduce Risk of Breast Cancer Cite
  Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. Medication Use to Reduce Risk of Breast Cancer. JAMA. American Medical Association (AMA); 2019; 322:857 10.1001/jama.2019.11885
• Breast-conserving surgery for pure non-classic lobular carcinoma in situ: A single institution's experience Cite
  Hoffman DI, Zhang PJ, Tchou J. Breast-conserving surgery for pure non-classic lobular carcinoma in situ: A single institution's experience. Surgical Oncology. Elsevier BV; 2019; 28:190-194 10.1016/j.suronc.2019.01.009
• Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ Cite
  Nakhlis F, Harrison BT, Giess CS, Lester SC, Hughes KS, Coopey SB, et al. Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2018; 26:55-61 10.1245/s10434-018-6937-0
• Lobular Carcinoma In Situ: Risk Factor or Cancer Precursor? Cite
  Sullivan KM, Flanagan MR, Kilgore MR, Anderson BO. Lobular Carcinoma In Situ: Risk Factor or Cancer Precursor?. Atypical Breast Proliferative Lesions and Benign Breast Disease. Springer International Publishing; 2018;:21-36 10.1007/978-3-319-92657-5_2
• Surgical upgrade rate of breast atypia to malignancy: An academic center's experience and validation of a predictive model Cite
  Linsk A, Mehta TS, Dialani V, Brook A, Chadashvili T, Houlihan MJ, et al. Surgical upgrade rate of breast atypia to malignancy: An academic center's experience and validation of a predictive model. The Breast Journal. Wiley; 2017; 24:115-119 10.1111/tbj.12885
• Survival following breast-conserving therapy is equal to that following mastectomy in young women with early-stage invasive lobular carcinoma Cite
  Yu T, Liu Y, Hu X, Di G. Survival following breast-conserving therapy is equal to that following mastectomy in young women with early-stage invasive lobular carcinoma. European Journal of Surgical Oncology. Elsevier BV; 2018; 44:1703-1707 10.1016/j.ejso.2018.06.026
• Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia Cite
  Degnim AC, Winham SJ, Frank RD, Pankratz VS, Dupont WD, Vierkant RA, et al. Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018; 36:1840-1846 10.1200/jco.2017.75.9480
• Lobular carcinoma in situ (LCIS) and its variants Cite
  Collins LC. Lobular carcinoma in situ (LCIS) and its variants. Pathology. Elsevier BV; 2018; 50:S11 10.1016/j.pathol.2017.12.028
• Personal history of proliferative breast disease with atypia and risk of multifocal breast cancer Cite
  Nutter EL, Weiss JE, Marotti JD, Barth RJ, Eliassen MS, Goodrich ME, et al. Personal history of proliferative breast disease with atypia and risk of multifocal breast cancer. Cancer. Wiley; 2017; 124:1350-1357 10.1002/cncr.31202
• Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study Cite
  Mullooly M, Khodr ZG, Dallal CM, Nyante SJ, Sherman ME, Falk R, et al. Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study. American Journal of Epidemiology. Oxford University Press (OUP); 2017; 186:1329-1340 10.1093/aje/kwx206
• Breast cancer risk associated with atypical hyperplasia and lobular carcinoma in situ initially diagnosed on core-needle biopsy Cite
  Donaldson AR, McCarthy C, Goraya S, Pederson HJ, Sturgis CD, Grobmyer SR, et al. Breast cancer risk associated with atypical hyperplasia and lobular carcinoma in situ initially diagnosed on core-needle biopsy. Cancer. Wiley; 2017; 124:459-465 10.1002/cncr.31061
• Factors Influencing Management and Outcome in Patients with Occult Breast Cancer with Axillary Lymph Node Involvement: Analysis of the National Cancer Database Cite
  Hessler LK, Molitoris JK, Rosenblatt PY, Bellavance EC, Nichols EM, Tkaczuk KHR, et al. Factors Influencing Management and Outcome in Patients with Occult Breast Cancer with Axillary Lymph Node Involvement: Analysis of the National Cancer Database. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2017; 24:2907-2914 10.1245/s10434-017-5928-x
• Survival outcomes of patients with lobular carcinoma in situ who underwent bilateral mastectomy or partial mastectomy Cite
  Xie Z, Sun J, Hu Z, Wu Y, Liu P, Tang J, et al. Survival outcomes of patients with lobular carcinoma in situ who underwent bilateral mastectomy or partial mastectomy. European Journal of Cancer. Elsevier BV; 2017; 82:6-15 10.1016/j.ejca.2017.05.030
• Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study Cite
  Mullooly M, Khodr ZG, Dallal CM, Nyante SJ, Sherman ME, Falk R, et al. Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study. American Journal of Epidemiology. Oxford University Press (OUP); 2017; 186:1329-1340 10.1093/aje/kwx206
• Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review Cite
  De Brot M, Koslow Mautner S, Muhsen S, Andrade VP, Mamtani A, Murray M, et al. Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 165:411-420 10.1007/s10549-017-4334-1
• Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ Cite
  Wong SM, King T, Boileau J, Barry WT, Golshan M. Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2017; 24:2509-2517 10.1245/s10434-017-5867-6
• Is the outcome at surgery different when flat epithelial atypia and lobular neoplasia are found in association at biopsy? Cite
  El Khoury M, Sanchez LM, Lalonde L, Trop I, David J, Mesurolle B. Is the outcome at surgery different when flat epithelial atypia and lobular neoplasia are found in association at biopsy?. The British Journal of Radiology. British Institute of Radiology; 2017; 90:20160750 10.1259/bjr.20160750
• Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program Cite
  Doebar SC, Slaets L, Cardoso F, Giordano SH, Bartlett JM, Tryfonidis K, et al. Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Modern Pathology. Springer Science and Business Media LLC; 2017; 30:509-518 10.1038/modpathol.2016.229
• Atypical Lobular Hyperplasia and Lobular Carcinoma In Situ Cite
  Hwang H, Sahoo S. Atypical Lobular Hyperplasia and Lobular Carcinoma In Situ. A Comprehensive Guide to Core Needle Biopsies of the Breast. Springer International Publishing; 2016;:561-593 10.1007/978-3-319-26291-8_14
• Lobular neoplasia diagnosed on breast Core biopsy: frequency of carcinoma on excision and implications for management Cite
  Calhoun BC, Collie AM, Lott-Limbach AA, Udoji EN, Sieck LR, Booth CN, et al. Lobular neoplasia diagnosed on breast Core biopsy: frequency of carcinoma on excision and implications for management. Annals of Diagnostic Pathology. Elsevier BV; 2016; 25:20-25 10.1016/j.anndiagpath.2016.07.009
• Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women Cite
  Degnim AC, Dupont WD, Radisky DC, Vierkant RA, Frank RD, Frost MH, et al. Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. Cancer. Wiley; 2016; 122:2971-2978 10.1002/cncr.30153
• Clinicopathologic Features of Pleomorphic Invasive Lobular Carcinoma: Comparison with Classic Invasive Lobular Carcinoma Cite
  Yeom C, Kim H, Kwon S, Kang SH. Clinicopathologic Features of Pleomorphic Invasive Lobular Carcinoma: Comparison with Classic Invasive Lobular Carcinoma. Journal of Breast Disease. Korean Breast Cancer Society; 2016; 4:10-15 10.14449/jbd.2016.4.1.10
• Management of atypical lobular hyperplasia, atypical ductal hyperplasia, and lobular carcinoma in situ Cite
  Clauser P, Marino MA, Baltzer PA, Bazzocchi M, Zuiani C. Management of atypical lobular hyperplasia, atypical ductal hyperplasia, and lobular carcinoma in situ. Expert Review of Anticancer Therapy. Informa UK Limited; 2016; 16:335-346 10.1586/14737140.2016.1143362
• Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies Cite
  Renshaw AA, Gould EW. Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies. Pathology. Elsevier BV; 2016; 48:25-29 10.1016/j.pathol.2015.11.015
• Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases Cite
  Cutuli B, De Lafontan B, Kirova Y, Auvray H, Tallet A, Avigdor S, et al. Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases. Radiation Oncology. Springer Science and Business Media LLC; 2015; 10 10.1186/s13014-015-0379-7
• Outcomes of patients with lobular in situ neoplasia of the breast: The role of vacuum-assisted biopsy Cite
  Parkin C, Garewal S, Waugh P, Maxwell A. Outcomes of patients with lobular in situ neoplasia of the breast: The role of vacuum-assisted biopsy. The Breast. Elsevier BV; 2014; 23:651-655 10.1016/j.breast.2014.06.016
• When is excision necessary for atypical lobular hyperplasia and lobular carcinoma in situ? Cite
  Rendi MH. When is excision necessary for atypical lobular hyperplasia and lobular carcinoma in situ?. Breast Cancer Management. Future Medicine Ltd; 2014; 3:145-153 10.2217/bmt.13.78
• Synchronous lobular carcinoma in situ and invasive lobular cancer: Marker or precursor for invasive lobular carcinoma Cite
  Wallace A, Xiang D, Hockman L, Arya M, Jeffress J, Wang Z, et al. Synchronous lobular carcinoma in situ and invasive lobular cancer: Marker or precursor for invasive lobular carcinoma. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2014; 40:1245-1249 10.1016/j.ejso.2014.04.007
• Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast Cite
  Sawyer E, Roylance R, Petridis C, Brook MN, Nowinski S, Papouli E, et al. Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. PLoS Genetics. Public Library of Science (PLoS); 2014; 10:e1004285 10.1371/journal.pgen.1004285
• Evolving concepts in breast lobular neoplasia and invasive lobular carcinoma, and their impact on imaging methods Cite
  Oliveira TMG, Elias J, Melo AF, Teixeira SR, Filho SC, Gonçalves LM, et al. Evolving concepts in breast lobular neoplasia and invasive lobular carcinoma, and their impact on imaging methods. Insights into Imaging. Springer Science and Business Media LLC; 2014; 5:183-194 10.1007/s13244-014-0324-6
• Cigarette Smoking, Physical Activity, and Alcohol Consumption as Predictors of Cancer Incidence among Women at High Risk of Breast Cancer in the NSABP P-1 Trial Cite
  Land SR, Liu Q, Wickerham DL, Costantino JP, Ganz PA. Cigarette Smoking, Physical Activity, and Alcohol Consumption as Predictors of Cancer Incidence among Women at High Risk of Breast Cancer in the NSABP P-1 Trial. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2014; 23:823-832 10.1158/1055-9965.epi-13-1105-t
• Is carcinomain situa precursor lesion of invasive breast cancer? Cite
  To T, Wall C, Baines CJ, Miller AB. Is carcinomain situa precursor lesion of invasive breast cancer?. International Journal of Cancer. Wiley; 2014; 135:1646-1652 10.1002/ijc.28803
• Risk of Local Failure in Breast Cancer Patients With Lobular Carcinoma In Situ at the Final Surgical Margins: Is Re-excision Necessary? Cite
  Sadek BT, Shenouda MN, Abi Raad RF, Niemierko A, Keruakous AR, Goldberg SI, et al. Risk of Local Failure in Breast Cancer Patients With Lobular Carcinoma In Situ at the Final Surgical Margins: Is Re-excision Necessary?. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2013; 87:726-730 10.1016/j.ijrobp.2013.08.012
• Differences in Mammographic Density Decline over Time in Breast Cancer Cases and Women at High Risk for Breast Cancer Cite
  ME W, LL R, AS Q, KD C, A W, MB T. Differences in Mammographic Density Decline over Time in Breast Cancer Cases and Women at High Risk for Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2013; 22:476.1-476 10.1158/1055-9965.epi-13-0078
• Long-Term Follow-up of Lobular Neoplasia (Atypical Lobular Hyperplasia/Lobular Carcinoma In Situ) Diagnosed on Core Needle Biopsy Cite
  Shah-Khan MG, Geiger XJ, Reynolds C, Jakub JW, DePeri ER, Glazebrook KN. Long-Term Follow-up of Lobular Neoplasia (Atypical Lobular Hyperplasia/Lobular Carcinoma In Situ) Diagnosed on Core Needle Biopsy. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2012; 19:3131-3138 10.1245/s10434-012-2534-9
• The Significance of Lobular Carcinoma In Situ and Atypical Lobular Hyperplasia of the Breast Cite
  Lewis JL, Lee DY, Tartter PI. The Significance of Lobular Carcinoma In Situ and Atypical Lobular Hyperplasia of the Breast. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2012; 19:4124-4128 10.1245/s10434-012-2538-5
• Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions Cite
  Andrade VP, Ostrovnaya I, Seshan VE, Morrogh M, Giri D, Olvera N, et al. Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. Breast Cancer Research. Springer Science and Business Media LLC; 2012; 14 10.1186/bcr3222
• High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients Cite
  Vincent-Salomon A, Hajage D, Rouquette A, Cédenot A, Gruel N, Alran S, et al. High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients. The Breast. Elsevier BV; 2012; 21:380-383 10.1016/j.breast.2012.03.005
• Management of Patients Diagnosed With Lobular Carcinoma in Situ at Needle Core Biopsy at a Community-Based Outpatient Facility Cite
  Destounis SV, Murphy PF, Seifert PJ, Somerville PA, Arieno AL, Morgan RC, et al. Management of Patients Diagnosed With Lobular Carcinoma in Situ at Needle Core Biopsy at a Community-Based Outpatient Facility. American Journal of Roentgenology. American Roentgen Ray Society; 2012; 198:281-287 10.2214/ajr.11.7043
• Nonsurgical Management of High-Risk Lesions Diagnosed at Core Needle Biopsy: Can Malignancy Be Ruled Out Safely With Breast MRI? Cite
  Linda A, Zuiani C, Furlan A, Lorenzon M, Londero V, Girometti R, et al. Nonsurgical Management of High-Risk Lesions Diagnosed at Core Needle Biopsy: Can Malignancy Be Ruled Out Safely With Breast MRI?. American Journal of Roentgenology. American Roentgen Ray Society; 2012; 198:272-280 10.2214/ajr.11.7040
• Surgical Outcome of Biopsy-Proven Lobular Neoplasia: Is There Any Difference Between Lobular Carcinoma In Situ and Atypical Lobular Hyperplasia? Cite
  Ibrahim N, Bessissow A, Lalonde L, Mesurolle B, Trop I, Lisbona A, et al. Surgical Outcome of Biopsy-Proven Lobular Neoplasia: Is There Any Difference Between Lobular Carcinoma In Situ and Atypical Lobular Hyperplasia?. American Journal of Roentgenology. American Roentgen Ray Society; 2012; 198:288-291 10.2214/ajr.11.7212
• Accuracy and Completeness of Pathology Reporting — Impact on Partial Breast Irradiation Eligibility Cite
  Pignol J, Rakovitch E, Zeppieri J, Hanna W. Accuracy and Completeness of Pathology Reporting — Impact on Partial Breast Irradiation Eligibility. Clinical Oncology. Elsevier BV; 2012; 24:177-182 10.1016/j.clon.2011.09.004
• The Diagnosis of Pleomorphic Lobular Carcinoma In Situ Warrants Complete Excision with Negative Margins Cite
  Middleton LP. The Diagnosis of Pleomorphic Lobular Carcinoma In Situ Warrants Complete Excision with Negative Margins. Current Breast Cancer Reports. Springer Science and Business Media LLC; 2012; 4:96-101 10.1007/s12609-012-0072-x
• Low Frequency of Cancer Occurrence in Same Breast Quadrant Diagnosed with Lobular Neoplasia at Percutaneous Needle Biopsy Cite
  Provencher L, Jacob S, Côté G, Hogue J, Desbiens C, Poirier B, et al. Low Frequency of Cancer Occurrence in Same Breast Quadrant Diagnosed with Lobular Neoplasia at Percutaneous Needle Biopsy. Radiology. Radiological Society of North America (RSNA); 2012; 263:43-52 10.1148/radiol.11111293
• Lobular neoplasia on core biopsy: Is excision always indicated? Cite
  Makarewich CA, Rosenkranz KM. Lobular neoplasia on core biopsy: Is excision always indicated?. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:75-75 10.1200/jco.2011.29.27_suppl.75
• Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality? Cite
  Yerushalmi R, Tyldesley S, Woods R, Kennecke H, Speers C, Gelmon K. Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?. Annals of Oncology. Elsevier BV; 2011; 23:876-881 10.1093/annonc/mdr326
• Mammographic Breast Density and Subsequent Risk of Breast Cancer in Postmenopausal Women According to Tumor Characteristics Cite
  Yaghjyan L, Colditz GA, Collins LC, Schnitt SJ, Rosner B, Vachon C, et al. Mammographic Breast Density and Subsequent Risk of Breast Cancer in Postmenopausal Women According to Tumor Characteristics. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2011; 103:1179-1189 10.1093/jnci/djr225
• Dietary Glycemic Load, Glycemic Index, and Carbohydrate and Risk of Breast Cancer in the Women's Health Initiative Cite
  Shikany JM, Redden DT, Neuhouser ML, Chlebowski RT, Rohan TE, Simon MS, et al. Dietary Glycemic Load, Glycemic Index, and Carbohydrate and Risk of Breast Cancer in the Women's Health Initiative. Nutrition and Cancer. Informa UK Limited; 2011; 63:899-907 10.1080/01635581.2011.587227
• Breast cancer multifocality, disease extent, and survival Cite
  Tot T, Gere M, Pekár G, Tarján M, Hofmeyer S, Hellberg D, et al. Breast cancer multifocality, disease extent, and survival. Human Pathology. Elsevier BV; 2011; 42:1761-1769 10.1016/j.humpath.2011.02.002
• Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast–A review Cite
  Hussain M, Cunnick G. Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast–A review. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2011; 37:279-289 10.1016/j.ejso.2011.01.009
• Two distinct molecular subgroups of lobular carcinoma in situ associated with invasive lobular carcinoma. Cite
  Andrade VP, Morrogh M, Sakr R, Muhsen S, Paik W, Li-Xuan Q, et al. Two distinct molecular subgroups of lobular carcinoma in situ associated with invasive lobular carcinoma.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:e21077-e21077 10.1200/jco.2010.28.15_suppl.e21077
• Risk for subsequent breast cancer after lobular carcinoma in situ: Do clinical factors matter? Cite
  Muhsen S, Morrogh M, Andrade AP, Sakr R, Paik W, Morrow M, et al. Risk for subsequent breast cancer after lobular carcinoma in situ: Do clinical factors matter?. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1593-1593 10.1200/jco.2010.28.15_suppl.1593
• Factors predicting in-breast tumor recurrence after breast-conserving surgery Cite
  Mechera R, Viehl CT, Oertli D. Factors predicting in-breast tumor recurrence after breast-conserving surgery. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2008; 116:171-177 10.1007/s10549-008-0187-y
• Tea Consumption and Risk of Breast Cancer Cite
  Kumar N, Titus-Ernstoff L, Newcomb PA, Trentham-Dietz A, Anic G, Egan KM. Tea Consumption and Risk of Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2009; 18:341-345 10.1158/1055-9965.epi-08-0819
• The Use of Herbal Preparations to Alleviate Climacteric Disorders and Risk of Postmenopausal Breast Cancer in a German Case-Control Study Cite
  Obi N, Chang-Claude J, Berger J, Braendle W, Slanger T, Schmidt M, et al. The Use of Herbal Preparations to Alleviate Climacteric Disorders and Risk of Postmenopausal Breast Cancer in a German Case-Control Study. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2009; 18:2207-2213 10.1158/1055-9965.epi-09-0298
• The Changing Incidence of In situ and Invasive Ductal and Lobular Breast Carcinomas: United States, 1999-2004 Cite
  Eheman CR, Shaw KM, Ryerson AB, Miller JW, Ajani UA, White MC. The Changing Incidence of In situ and Invasive Ductal and Lobular Breast Carcinomas: United States, 1999-2004. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2009; 18:1763-1769 10.1158/1055-9965.epi-08-1082
• The t10,c12 isomer of conjugated linoleic acid stimulates mammary tumorigenesis in transgenic mice over-expressing erbB2 in the mammary epithelium Cite
  Ip MM, McGee SO, Masso-Welch PA, Ip C, Meng X, Ou L, et al. The t10,c12 isomer of conjugated linoleic acid stimulates mammary tumorigenesis in transgenic mice over-expressing erbB2 in the mammary epithelium. Carcinogenesis. Oxford University Press (OUP); 2007; 28:1269-1276 10.1093/carcin/bgm018